ES2171577T3 - Kappa-opiaceos para enfermedades intestinales inflamatorias. - Google Patents

Kappa-opiaceos para enfermedades intestinales inflamatorias.

Info

Publication number
ES2171577T3
ES2171577T3 ES96109915T ES96109915T ES2171577T3 ES 2171577 T3 ES2171577 T3 ES 2171577T3 ES 96109915 T ES96109915 T ES 96109915T ES 96109915 T ES96109915 T ES 96109915T ES 2171577 T3 ES2171577 T3 ES 2171577T3
Authority
ES
Spain
Prior art keywords
sub
sup
hal
nhcoa
nha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96109915T
Other languages
English (en)
Spanish (es)
Inventor
Andrew Dr Barber
Christoph Dr Seyfried
Gerd Bartoszyk
Rudolf Dr Gottschlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2171577T3 publication Critical patent/ES2171577T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ES96109915T 1995-06-28 1996-06-20 Kappa-opiaceos para enfermedades intestinales inflamatorias. Expired - Lifetime ES2171577T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19523502A DE19523502A1 (de) 1995-06-28 1995-06-28 Kappa-Opiatagonisten für entzündliche Darmerkrankungen

Publications (1)

Publication Number Publication Date
ES2171577T3 true ES2171577T3 (es) 2002-09-16

Family

ID=7765475

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96109915T Expired - Lifetime ES2171577T3 (es) 1995-06-28 1996-06-20 Kappa-opiaceos para enfermedades intestinales inflamatorias.

Country Status (26)

Country Link
US (2) US5776972A (enExample)
EP (1) EP0752246B1 (enExample)
JP (2) JP4415075B2 (enExample)
KR (1) KR100501612B1 (enExample)
CN (1) CN1119147C (enExample)
AR (1) AR004671A1 (enExample)
AT (1) ATE214275T1 (enExample)
AU (1) AU708699B2 (enExample)
BR (1) BR9602915A (enExample)
CA (1) CA2179955C (enExample)
CO (1) CO4700454A1 (enExample)
CZ (1) CZ289805B6 (enExample)
DE (2) DE19523502A1 (enExample)
DK (1) DK0752246T3 (enExample)
ES (1) ES2171577T3 (enExample)
HU (1) HU226976B1 (enExample)
NO (1) NO309674B1 (enExample)
PL (1) PL185537B1 (enExample)
PT (1) PT752246E (enExample)
RU (1) RU2190401C2 (enExample)
SI (1) SI0752246T1 (enExample)
SK (1) SK283497B6 (enExample)
TR (1) TR199600497A2 (enExample)
TW (1) TW430557B (enExample)
UA (1) UA51615C2 (enExample)
ZA (1) ZA965480B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
EP0948964B1 (en) * 1996-12-02 2003-04-02 Kyorin Pharmaceutical Co., Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
US6133307A (en) * 1997-04-30 2000-10-17 Warner-Lambert Company Certain benzofuranyl-N-[pyrrolidin-1-YL]-N-methyl-acetamide derivatives useful as opioid agonists
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
JP2003526594A (ja) * 1997-07-14 2003-09-09 アドラー コーポレーション カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20050176746A1 (en) * 2002-05-17 2005-08-11 Frank Weber Use of compounds that are effective as selective opiate receptor modulators
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
TWI334349B (en) * 2003-07-04 2010-12-11 Santen Pharmaceutical Co Ltd Pain threshold reduction depressant
US7642274B2 (en) 2003-07-04 2010-01-05 Santen Pharmaceutical Co., Ltd. Inhibitor of pain threshold decrease
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
US7160902B2 (en) * 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use
PL2136801T3 (pl) * 2007-03-30 2013-01-31 Tioga Pharmaceuticals Inc Agoniści kappa-opioidów do leczenia zespołu jelita drażliwego w postaci zmiennej i z dominującą biegunką
CN104271552B (zh) * 2012-03-05 2017-08-08 雷迪博士实验室有限公司 作为kappa阿片样物质受体(kor)激动剂的取代的杂环乙酰胺
WO2015114660A1 (en) * 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists
WO2018119108A1 (en) 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Splid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
US5232266A (en) * 1989-07-24 1993-08-03 Mork William J Upholstered article of furniture with interchangeable seating module
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
CN1145781A (zh) 1997-03-26
SK84396A3 (en) 1997-04-09
JP4415075B2 (ja) 2010-02-17
TR199600497A2 (tr) 1997-01-21
AU708699B2 (en) 1999-08-12
NO962720D0 (no) 1996-06-27
SK283497B6 (sk) 2003-08-05
DE59608861D1 (de) 2002-04-18
DE19523502A1 (de) 1997-01-02
CA2179955C (en) 2008-10-07
US5776972A (en) 1998-07-07
AR004671A1 (es) 1999-03-10
JPH0920659A (ja) 1997-01-21
PL185537B1 (pl) 2003-05-30
US5977161A (en) 1999-11-02
CO4700454A1 (es) 1998-12-29
EP0752246A2 (de) 1997-01-08
HU226976B1 (en) 2010-04-28
PT752246E (pt) 2002-09-30
JP5308056B2 (ja) 2013-10-09
NO962720L (no) 1996-12-30
DK0752246T3 (da) 2002-05-13
EP0752246A3 (de) 1997-02-26
KR100501612B1 (ko) 2005-10-12
PL314996A1 (en) 1997-01-06
JP2008201794A (ja) 2008-09-04
KR970000230A (ko) 1997-01-21
HUP9601798A1 (hu) 1998-03-30
UA51615C2 (uk) 2002-12-16
CA2179955A1 (en) 1996-12-29
CZ186696A3 (en) 1997-01-15
AU5616296A (en) 1997-01-09
RU2190401C2 (ru) 2002-10-10
NO309674B1 (no) 2001-03-12
BR9602915A (pt) 1998-04-22
EP0752246B1 (de) 2002-03-13
CN1119147C (zh) 2003-08-27
CZ289805B6 (cs) 2002-04-17
ZA965480B (en) 1997-01-27
ATE214275T1 (de) 2002-03-15
TW430557B (en) 2001-04-21
SI0752246T1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2171577T3 (es) Kappa-opiaceos para enfermedades intestinales inflamatorias.
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
PA8452201A1 (es) Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4"sustituidos.
ES2170605A1 (es) Nuevos fotoiniciadores de o-aciloximas.
NO992705L (no) 3-pyridylenantiomere og deres anvendelse som analgetika
GT199700016A (es) Derivados de triazol utiles en terapia
ES2175127T3 (es) Derivados de la quinazolina y su uso.
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
KR880009910A (ko) 리폭시게네이즈 억제 화합물
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
AR055393A2 (es) Uso de un derivado de carboestirilo para la preparcion de una composicion farmaceutica para tratar enfermedades oftalmologicas
ES2072263T3 (es) Derivados de 4-aminopiridina.
ES2127789T3 (es) Derivados de 1,2,4-triazol 4-sustituidos.
ES2189173T3 (es) Derivados de 20-aril-5alfa-pregnano.
PT832886E (pt) Derivados de flavonas processo para a sua preparacao e as composicoes farmaceuticas que os contem
KR950010891A (ko) 내성 종양을 치료하는 방법
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
RU93047669A (ru) Производные фенилбензамидов, способ их получения, фунгицидная композиция на их основе и способ фунгицидной борьбы
ES2181927T3 (es) Derivados de 1-metilcarbapenem.
MX9604765A (es) Derivados de 5-heterociclico 1,5-benzodiazepinas que modulan la cck o gastrina.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ES2160801T3 (es) Sulfonilaminocarboniltriazolinonas con halogeno alq(en)iltio-substituyentes, herbicidas y fungicidas.
DK0683170T3 (da) Glucopyranosidbenzothiophener

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752246

Country of ref document: ES